<DOC>
	<DOCNO>NCT01887288</DOCNO>
	<brief_summary>To evaluate Growth Modulation Index ( GMI ) combination metronomic capecitabine oral digoxin metastatic breast cancer</brief_summary>
	<brief_title>Capecitabine With Digoxin Metastatic Breast Cancer</brief_title>
	<detailed_description>In phase II study , Investigators combine metronomic capecitabine digoxin treat metastatic breast cancer patient progress anthracyclines taxanes . We hypothesize combination digoxin metronomic capecitabine may lead increase efficacy duration treatment without progression decrease side effect standard regimen .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>1 . Patients ≥ 18 year age histologically confirm , metastatic breast cancer resistant anthracyclines taxanes 2 . Anthracycline resistance define tumor progression treatment within 3 month last dose metastatic setting , recurrence within 6 month neoadjuvant adjuvant setting . Alternatively , minimum cumulative dose anthracycline 240 mg/m^2 ( doxorubicin ) 360 mg/m^2 ( epirubicin ) reach , contraindication use anthracycline , patient also eligible 3 . Taxane resistance define recurrence within 4 month last dose metastatic setting within 12 month adjuvant set 4 . Having progress antiHER2 hormonal therapy HER2 positive hormonereceptor positive breast cancer 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤ 2 life expectancy &gt; 3 month . 6 . Participants must least one target lesion define RECIST 1.1 allow evaluation tumor response 7 . Absolute neutrophil count ≥ 1500 mm3 , platelet count ≥ 100×109 L , hemoglobin ≥ 8.5 g/dL 8 . Serum creatinine ≤1.5 time upper limit normal range , total bilirubin ≤ 2 mg/dL , AST/ALT ≤ 5 time upper limit normal range 9 . No remain grade 2 high toxicity prior cancer therapy unless judge clinically insignificant Principal Investigator 10 . At least three ( 3 ) week prior chemotherapy 11 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable contraceptive method ( abstinence , oral contraceptive double barrier method ) duration study 30 day follow last dose study drug , must negative urine serum pregnancy test within 2 week prior begin treatment trial . 1 . Inadequate renal function calculate creatinine clearance le 51 mL/min . 2 . History ventricular fibrillation , sinus node AV nodal disease , Wolff Parkinson White Syndrome , hemodynamically significant life threaten cardiac arrhythmia . 3 . Uncontrolled cardiac disease , congestive heart failure , angina hypertension . 4 . Myocardial infarction unstable angina within 2 month treatment . 5 . Known human immunodeficiency virus ( HIV ) infection chronic active Hepatitis B C ( patient NOT require test presence virus prior therapy protocol ) . 6 . Active clinically serious infection &gt; CTCAE ( version 4.03 ) Grade 2 . 7 . Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . 8 . Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 week first dose study drug . 9 . Any hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 week first dose study drug . 10 . Serious nonhealing wound , ulcer , bone fracture . 11 . Major surgery significant traumatic injury within 2 week first study drug . 12 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 13 . Concurrent severe illness active infection , psychiatric illness/social situation would limit safety compliance study requirement . 14 . Currently anticoagulation therapy Coumadin , switch form anticoagulation . 15 . Patients symptomatic untreated brain metastasis leptomeningeal metastasis treat still symptomatic require use steroid within past two week . 16 . Patients receive investigational agent . Pregnant Lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>